PharmaCorp Rx Inc. PCRX.V
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 51.46% | 112.06% | -110.70% | -11.82% | -264.65% |
| Total Depreciation and Amortization | -6.15% | 4.77% | 51.92% | 18.42% | 4.36% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -308.93% | -75.61% | 29.09% | 697.90% | -332.73% |
| Change in Net Operating Assets | 114.13% | -277.51% | 222.75% | 1,737.56% | 110.87% |
| Cash from Operations | 130.62% | -279.26% | 171.74% | 379.57% | -258.25% |
| Capital Expenditure | 19.90% | -348.20% | -100.92% | 7,420.87% | -10.16% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | 107.21% | -910.44% | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 199.22% | 99.42% | -- | -- | -- |
| Cash from Investing | -272.17% | 95.60% | 71.23% | -161.66% | -12,026.74% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 73.05% | 33.77% | -163.61% | -54.43% | 22.09% |
| Issuance of Common Stock | -- | -- | 477.83% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -39.89% | -16.78% | 2,572.53% | -- | -- |
| Cash from Financing | -27.38% | -98.75% | 596.14% | 7,927.97% | 18.98% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 125.09% | -112.20% | 554.07% | -35.10% | -6,838.12% |